Let's talk medical research

Autoimmune hepatitis (AIH) is a rare disease in which the body's immune system attacks the cells of the liver, causing chronic inflammation and potentially serious damage to liver cells.

It’s no secret that clinical trial recruitment can be challenging. From initial engagement with the right patients, to tracking recruitment at the site level, to juggling vendors, it’s no wonder patient recruitment takes an estimated 30% of the trial process.

Inflammatory bowel disease (IBD) is characterized by a group of intestinal disorders that cause inflammation of the digestive tract. The two most common kinds of IBD are ulcerative colitis (UC) and Crohn’s disease. Often, patients with Crohn’s and UC present similar symptoms, such as abdominal pain, diarrhea, and rectal bleeding, but the two conditions are actually quite different. We look at the ...

Are you spending time and money on clinical trial advertising that’s not delivering? It can be frustrating to put resources into spreading the word about your study, only to find that the patients who make it to your sites are not right for your trial. According to a survey Antidote conducted of 4,000+ patients, 52% of patients found out about clinical trial opportunities through an ...

Enrolling in a clinical trial is a big decision. It’s important to speak with friends, family members, health care providers, and other people living with your condition to make your decision about participation. But even then, the process can be a bit confusing.

Getting a clinical trial started is often a collaborative effort between a number of different teams, from sponsors to sites to patient recruitment organizations. When it comes to clinical trial recruitment companies, what exactly does study start up look like? We spoke with Antidote’s Senior Manager of Strategic Client Services, Amrita Bhatt, about what it takes to kick off a new clinical trial ...

More than 80,000 people in the US will be diagnosed with bladder cancer this year. Treatment options have come a long way, and now include surgery, radiation, and chemotherapy — but many come with less than desirable side effects, and bladder cancer may recur. Research in this area is critical.

We recently announced a collaboration with Ben’s Friends, a network of online communities for people impacted by rare disease, and MyRareData, an organization that facilitates fundraising for advocacy groups through data, to bring information about clinical trials to the rare disease community.

With what we’re learning from the COVID-19 pandemic, can we create a permanent solution to keep the patient at the heart of clinical research? Last week a panel of experts, including our CEO, Laurent Schockmel, teamed up for an Ogilvy Consulting webinar, during which they discussed key industry considerations when it comes to putting patient centricity into action.

Biliary tract cancer (BTC) is a rare form of cancer that develops in the bile duct system, which connects the liver, gallbladder, and small intestine, moving bile to the small intestine. There are three types of biliary tract cancer: Intrahepatic cholangiocarcinoma (ICC, or bile duct cancer), extrahepatic cholangiocarcinoma, and gallbladder cancer. While this form of cancer is particularly tough ...